252 related articles for article (PubMed ID: 26074449)
21. Proteomics in diagnosis of prostate cancer.
Davalieva K; Polenakovic M
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2015; 36(1):5-36. PubMed ID: 26076772
[TBL] [Abstract][Full Text] [Related]
22. Urinary proteome profiling using 2D-DIGE and LC-MS/MS.
Weeks ME
Methods Mol Biol; 2010; 658():293-309. PubMed ID: 20839112
[TBL] [Abstract][Full Text] [Related]
23. Proteomics of rat prostate lobes treated with 2-N-hydroxylamino-1-methyl-6-phenylimidazo[4,5-b]pyridine, 5alpha-dihydrotestosterone, individually and in combination.
Boyiri T; Somiari RI; Russell S; Aliaga C; El-Bayoumy K
Int J Oncol; 2009 Sep; 35(3):559-67. PubMed ID: 19639176
[TBL] [Abstract][Full Text] [Related]
24. Expression analysis of thrombospondin 2 in prostate cancer and benign prostatic hyperplasia.
Matos AR; Coutinho-Camillo CM; Thuler LC; Fonseca FP; Soares FA; Silva EA; Gimba ER
Exp Mol Pathol; 2013 Jun; 94(3):438-44. PubMed ID: 23470460
[TBL] [Abstract][Full Text] [Related]
25. Identification of potential complementary serum biomarkers to differentiate prostate cancer from benign prostatic hyperplasia using gel- and lectin-based proteomics analyses.
Jayapalan JJ; Ng KL; Razack AH; Hashim OH
Electrophoresis; 2012 Jul; 33(12):1855-62. PubMed ID: 22740474
[TBL] [Abstract][Full Text] [Related]
26. Construction and analysis of protein-protein interaction networks based on proteomics data of prostate cancer.
Chen C; Shen H; Zhang LG; Liu J; Cao XG; Yao AL; Kang SS; Gao WX; Han H; Cao FH; Li ZG
Int J Mol Med; 2016 Jun; 37(6):1576-86. PubMed ID: 27121963
[TBL] [Abstract][Full Text] [Related]
27. Analysis of proteins using DIGE and MALDI mass spectrometry.
Winnik WM; Dekroon RM; Jeong JS; Mocanu M; Robinette JB; Osorio C; Dicheva NN; Hamlett E; Alzate O
Methods Mol Biol; 2012; 854():47-66. PubMed ID: 22311753
[TBL] [Abstract][Full Text] [Related]
28. MALDI MS profiling of post-DRE urine samples highlights the potential of β-microseminoprotein as a marker for prostatic diseases.
Flatley B; Wilmott KG; Malone P; Cramer R
Prostate; 2014 Jan; 74(1):103-11. PubMed ID: 24115268
[TBL] [Abstract][Full Text] [Related]
29. Proteomic analysis of zoledronic-acid resistant prostate cancer cells unveils novel pathways characterizing an invasive phenotype.
Milone MR; Pucci B; Bifulco K; Iannelli F; Lombardi R; Ciardiello C; Bruzzese F; Carriero MV; Budillon A
Oncotarget; 2015 Mar; 6(7):5324-41. PubMed ID: 25481874
[TBL] [Abstract][Full Text] [Related]
30. Stage-related alterations in renal cell carcinoma--comprehensive quantitative analysis by 2D-DIGE and protein network analysis.
Junker H; Venz S; Zimmermann U; Thiele A; Scharf C; Walther R
PLoS One; 2011; 6(7):e21867. PubMed ID: 21760917
[TBL] [Abstract][Full Text] [Related]
31. 2D-DIGE proteomic analysis identifies new potential therapeutic targets for adrenocortical carcinoma.
Poli G; Ceni E; Armignacco R; Ercolino T; Canu L; Baroni G; Nesi G; Galli A; Mannelli M; Luconi M
Oncotarget; 2015 Mar; 6(8):5695-706. PubMed ID: 25691058
[TBL] [Abstract][Full Text] [Related]
32. [Modified serum-guided immunoblotting for differential proteomic study of prostate cancer].
Zhang XB; Tang ZY; Zu XB; Qi L; Ruan JD
Zhonghua Nan Ke Xue; 2010 May; 16(5):438-44. PubMed ID: 20684326
[TBL] [Abstract][Full Text] [Related]
33. State of the art of 2D DIGE.
Arentz G; Weiland F; Oehler MK; Hoffmann P
Proteomics Clin Appl; 2015 Apr; 9(3-4):277-88. PubMed ID: 25400138
[TBL] [Abstract][Full Text] [Related]
34. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation.
De Nunzio C; Kramer G; Marberger M; Montironi R; Nelson W; Schröder F; Sciarra A; Tubaro A
Eur Urol; 2011 Jul; 60(1):106-17. PubMed ID: 21497433
[TBL] [Abstract][Full Text] [Related]
35. Frequent 14-3-3 sigma promoter methylation in benign and malignant prostate lesions.
Henrique R; Jerónimo C; Hoque MO; Carvalho AL; Oliveira J; Teixeira MR; Lopes C; Sidransky D
DNA Cell Biol; 2005 Apr; 24(4):264-9. PubMed ID: 15812243
[TBL] [Abstract][Full Text] [Related]
36. Multi-lectin Affinity Chromatography and Quantitative Proteomic Analysis Reveal Differential Glycoform Levels between Prostate Cancer and Benign Prostatic Hyperplasia Sera.
Totten SM; Adusumilli R; Kullolli M; Tanimoto C; Brooks JD; Mallick P; Pitteri SJ
Sci Rep; 2018 Apr; 8(1):6509. PubMed ID: 29695737
[TBL] [Abstract][Full Text] [Related]
37. Proteomics-based identification of a group of apoptosis-related proteins and biomarkers in gastric cancer.
Bai Z; Ye Y; Liang B; Xu F; Zhang H; Zhang Y; Peng J; Shen D; Cui Z; Zhang Z; Wang S
Int J Oncol; 2011 Feb; 38(2):375-83. PubMed ID: 21165559
[TBL] [Abstract][Full Text] [Related]
38. Prolactin- and testosterone-induced carboxypeptidase-D correlates with increased nitrotyrosines and Ki67 in prostate cancer.
Thomas LN; Merrimen J; Bell DG; Rendon R; Too CK
Prostate; 2015 Nov; 75(15):1726-36. PubMed ID: 26202060
[TBL] [Abstract][Full Text] [Related]
39. 2D-DIGE as a strategy to identify serum markers for the progression of prostate cancer.
Byrne JC; Downes MR; O'Donoghue N; O'Keane C; O'Neill A; Fan Y; Fitzpatrick JM; Dunn M; Watson RW
J Proteome Res; 2009 Feb; 8(2):942-57. PubMed ID: 19093873
[TBL] [Abstract][Full Text] [Related]
40. Search for potential markers for prostate cancer diagnosis, prognosis and treatment in clinical tissue specimens using amine-specific isobaric tagging (iTRAQ) with two-dimensional liquid chromatography and tandem mass spectrometry.
Garbis SD; Tyritzis SI; Roumeliotis T; Zerefos P; Giannopoulou EG; Vlahou A; Kossida S; Diaz J; Vourekas S; Tamvakopoulos C; Pavlakis K; Sanoudou D; Constantinides CA
J Proteome Res; 2008 Aug; 7(8):3146-58. PubMed ID: 18553995
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
